-
Midtgaard Kramer posted an update 3 hours, 28 minutes ago
OBJECTIVE The aim of this study is to assess the impact of specialized pediatric palliative care (PPC) on neonates with life-limiting conditions compared to standard care. STUDY DESIGN MEDLINE, PsycINFO, Cochrane Central Register of Controlled Trials, Web of Science, CINAHL, Scopus, and Embase databases were searched from January 2000 to Sep…[Read more]
-
Midtgaard Kramer posted an update 1 day, 3 hours ago
on, downregulation of the PI3K/Akt/mTOR pathway was shown to assist in the process of preventing chemoresistance.Inflammasomes can identify endogenous danger signals as an inflammatory immune response. As the most common inflammasome, the NLR pyrin family domain containing 3 (NLRP3) inflammasome is associated with the pathogenesis of different…[Read more]
-
Midtgaard Kramer posted an update 2 days, 2 hours ago
We thus believe that the novel PIM and PI3K/mTOR inhibitor, IBL-302, represents an exciting new potential treatment option for breast cancer, and that it should be considered for clinical investigation.The presence of an immature tumor vascular network contributes to cancer dissemination and the development of resistance to therapies. Strategies…[Read more]
-
Midtgaard Kramer posted an update 2 days, 10 hours ago
Our study extends the known distribution of this rare muscular dystrophy and presents the first detailed clinical and genetic characterizations of LGMD R7 cases from the Chinese population. Our work expands the mutation spectrum known for LGMD R7 and emphasizes the need for clinicians to consider TCAP mutations when evaluating patients with…[Read more]
-